Based on the Organogenesis Holdings Inc stock forecast from 4 analysts, the average analyst target price for Organogenesis Holdings Inc is USD 5.30 over the next 12 months. Organogenesis Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Organogenesis Holdings Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Organogenesis Holdings Inc’s stock price was USD 4.08. Organogenesis Holdings Inc’s stock price has changed by -6.21% over the past week, -20.85% over the past month and +38.31% over the last year.
No recent analyst target price found for Organogenesis Holdings Inc
No recent average analyst rating found for Organogenesis Holdings Inc
Company Overview Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts. Read Less
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, ...Read More
Frequently Asked Questions About Organogenesis Holdings Inc (ORGO) Stock
Based on ratings from 4 analysts Organogenesis Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ORGO's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ORGO is USD 5.30 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 3.8.
ORGO stock's Price/Earning ratio is 63.75.
Our analysis grades ORGO stock's Price / Earning ratio at F. This means that ORGO stock's Price/Earning ratio is above 73% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ORGO may be a overvalued for its sector.
The last closing price of ORGO's stock was USD 4.08.
The most recent market capitalization for ORGO is USD 0.65B.
Based on targets from 4 analysts, the average taret price for ORGO is projected at USD 5.30 over the next 12 months.
This means that ORGO's stock price may go up by +29.90% over the next 12 months.
We can't find any ETFs which contains Organogenesis Holdings Inc's stock.
As per our most recent records Organogenesis Holdings Inc has 869 Employees.
Organogenesis Holdings Inc's registered address is 85 Dan Road, Canton, MA, United States, 02021.
You can get more information about it from Organogenesis Holdings Inc's website at https://organogenesis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Organogenesis Holdings Inc (ORGO) Stock
Based on ratings from 4 analysts Organogenesis Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ORGO's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ORGO is USD 5.30 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 3.8.
ORGO stock's Price/Earning ratio is 63.75.
Our analysis grades ORGO stock's Price / Earning ratio at F. This means that ORGO stock's Price/Earning ratio is above 73% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ORGO may be a overvalued for its sector.
The last closing price of ORGO's stock was USD 4.08.
The most recent market capitalization for ORGO is USD 0.65B.
Based on targets from 4 analysts, the average taret price for ORGO is projected at USD 5.30 over the next 12 months.
This means that ORGO's stock price may go up by +29.90% over the next 12 months.
We can't find any ETFs which contains Organogenesis Holdings Inc's stock.
As per our most recent records Organogenesis Holdings Inc has 869 Employees.
Organogenesis Holdings Inc's registered address is 85 Dan Road, Canton, MA, United States, 02021.
You can get more information about it from Organogenesis Holdings Inc's website at https://organogenesis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ORGO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
